Client Story
How PHM used comprehensive molecular profiling and treatment abroad to achieve results.
Tom, a-76-year-old man, was diagnosed with metastatic prostate cancer when testosterone supplementation resulted in a huge PSA spike.
When he came to PHM a few months later, he had already started androgen deprivation therapy (ADT) to quickly lower his PSA levels and had undergone six rounds of chemotherapy.
Despite these standard treatments, Tom’s PSA levels began rising again, and the disease spread to his bones, where it becomes painful and difficult to treat. Tom and his physicians were gravely concerned about his prognosis; survival is frequently measured in months after the development of bone metastases.
Tom’s PHM Personal Care Team conducted an in-depth review of his clinical history and initial diagnostics. The team engaged leading experts with experience specific to his situation, collaborating to develop personalized treatment alternatives. They initiated one of the most powerful weapons in cancer management, comprehensive molecular profiling, to determine the best course of action.
PHM enrolled Tom in a clinical trial to receive an investigational imaging technique called a prostate-specific membrane antigen (PSMA) scan. If the scan was positive, Tom would be eligible for a promising new prostate cancer treatment called PSMA radioligand therapy (PRLT) that was only available in Germany.
The scan was positive, so Tom traveled to Germany to receive this cutting-edge therapy. The outcome of the PRLT therapy was better than anyone could have expected.
Tom showed an incredible initial response to the treatment, with disease regression throughout his body. Over the course of the next year, he received three additional treatments, his disease regressing further with each one. While PHM continues to monitor Tom carefully, he has not needed any additional PRLT treatments in more than two years.
With PHM’s identification and early adoption of the most promising cancer therapies, Tom received the priceless gift of more years of high quality of life with his grandchildren.
To learn more from PHM experts about clinical trials, download our information guide.
Discover our Why Wall
